Dr. Sabatino has over 15 years of research experience in multiple scientific disciplines, with 13 years in the cell and gene therapy field. She has built and led Cell, Vector (Lenti and Retro) Process and Analytical Development teams and supported CMC strategy for early and late-stage lifecycle of multiple CAR-T and TCR-T assets including the commercial products, YESCARTA™ and TECARTUS™ while at Kite Pharma. Additionally, she managed technical transfers to internal sites and CDMOs, PPQ planning for vector assets, product and process analytical characterization of company’s pipeline products at Autolus Therapeutics and Arcellx where she served as Process Development Head. Earlier in her career, Dr. Sabatino was a Staff Scientist at the Cell Processing Section of the National Institutes of Health (NIH), Bethesda (MD), where she focused on the translation and development of multiple novel manufacturing platforms in support of diverse early Phase I/II programs for single and multi-center clinical trials in Oncology and Regenerative Medicine. Dr. Sabatino received her Medical Degree and professional training in Medical Oncology from the University of Siena Medical School, Siena, Italy.